• Please log in or register to access this feature.

Original Article

You have free access to this content

Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia

  1. Yingmei Zhang MA1,
  2. Zhuo Zhang MA2,
  3. Jinmei Li BA2,
  4. Limin Li MA2,
  5. Xueying Han BA2,
  6. Lina Han MD2,
  7. Longhu Hu MD2,
  8. Shuye Wang MD2,
  9. Yanhong Zhao MD2,
  10. Xiaoxia Li MD2,
  11. Ying Zhang MD2,
  12. Shengjin Fan2,
  13. Chengfang Lv MD2,
  14. Yinghua Li MD2,
  15. Yanhua Su MD2,
  16. Hui Zhao BA1,
  17. Xin Zhang BA1,
  18. Jin Zhou MD2,†,*

Article first published online: 28 AUG 2012

DOI: 10.1002/cncr.27650

Issue

Cancer

Cancer

Volume 119, Issue 1, pages 115–125, 1 January 2013

Additional Information

How to Cite

Zhang, Y., Zhang, Z., Li, J., Li, L., Han, X., Han, L., Hu, L., Wang, S., Zhao, Y., Li, X., Zhang, Y., Fan, S., Lv, C., Li, Y., Su, Y., Zhao, H., Zhang, X. and Zhou, J. (2013), Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia. Cancer, 119: 115–125. doi: 10.1002/cncr.27650

Author Information

  1. 1

    Central Laboratory, the First Affiliated Hospital, Harbin Medical University, Harbin, Heilongjiang, China

  2. 2

    Department of Hematology, the First Affiliated Hospital, Harbin Medical University, Harbin, Heilongjiang, China

  1. †

    Fax: 86-0451-53670428

*Department of Hematology, the First Affiliated Hospital, Harbin Medical University, No. 23, Youzheng Street, Nangang District, Harbin, Heilongjiang, China, 150001

  1. †

    Fax: 86-0451-53670428

Publication History

  1. Issue published online: 17 DEC 2012
  2. Article first published online: 28 AUG 2012
  3. Manuscript Accepted: 24 APR 2012
  4. Manuscript Revised: 29 MAR 2012
  5. Manuscript Received: 29 DEC 2011

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (303K)

REFERENCES

  • 1
    Adès L, Chevret S, De Botton S, et al. Outcome of acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy in elderly patients: the European group experience. Leukemia. 2005; 19: 230-233.
  • 2
    Sanz MA, Vellenga E, Rayón C, et al. All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood. 2004; 104: 3490-3493.
  • 3
    Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood. 1999; 93: 4131-4143.
  • 4
    Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1999; 94: 1192-1200.
  • 5
    Mandelli F, Latagliata R, Avvisati G, et al; Italian GIMEMA Cooperative Group. Treatment of elderly patients (> or =60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. Leukemia. 2003; 17: 1085-1090.
  • 6
    Mathews V, George B, Chendamarai E, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol. 2010; 28: 3866-3871.
  • 7
    Mathews V, George B, Lakshmi KM, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006; 107: 2627-2632.
  • 8
    Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol. 2006; 17: 131-134.
  • 9
    Tallman MS. Treatment of elderly adults with acute promyelocytic leukemia: put the pedal to metal. Leuk Lymphoma. 2009; 50: 12-13.
  • 10
    Guha Mazumder DN. Chronic arsenic toxicity & human health. Indian J Med Res. 2008; 128: 436-447.
  • 11
    Zhou J, Zhang Y, Li J, et al. Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia. Blood. 2010; 115: 1697-1702.
  • 12
    Mathew A, Pandey M. Attributing death to cancer: cause-specific survival estimation. J Postgrad Med. 2002; 48: 322-326.
  • 13
    Kim HT. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res. 2007; 13( 2 Pt 1): 559-565.
  • 14
    Sanz MA, Lo Coco F, Martin G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000; 96: 1247-1253.
  • 15
    Zhang TD. Treatment of acute granulocytic leukemia with “Ai ling No. 1”—clinical analysis and experimental research [in Chinese]. Zhong Xi Yi Jie He Za Zhi. 1984; 4: 19-20.
  • 16
    Disperati P, Minden MD, Gupta V, et al. Acute promyelocytic leukemia in patients aged 70 years and over – a single center experience of unselected patients. Leuk Lymphoma. 2007; 48: 1654-1658.
  • 17
    Ferrara F, Finizio O, D'Arco A, Mastrullo L, Cantore N, Musto P. Acute promyelocytic leukemia in patients aged over 60 years: multicenter experience of 34 consecutive unselected patients. Anticancer Res. 2010; 30: 967-971.
  • 18
    Ohnishi K, Yoshida H, Shigeno K, et al. Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. Leukemia. 2002; 16: 617-622.
  • 19
    Westervelt P, Brown RA, Adkins DR, et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood. 2001; 98: 266-271.
  • 20
    Unnikrishnan D, Dutcher JP, Varshneya N, et al. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood. 2001; 97: 1514-1516.
View Full Article (HTML) Get PDF (303K)